Regulatory approval
Published by the Food and Drug Administration. Approved
ELAHERE is a folate receptor alpha (FRalpha)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FR-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | FOLR1 positive | Ovarian Epithelial Tumor | Mirvetuximab soravtansine | |
| FDA (1) | FOLR1 positive | High-Grade Serous Fallopian Tube Cancer | Mirvetuximab soravtansine | |
| FDA (1) | FOLR1 positive | Peritoneal Serous Carcinoma | Mirvetuximab soravtansine |